Biomea Fusion, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Biomea Fusion, Inc. (BMEA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 5.16 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-05
- Biomea Fusion, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 55.50K shares, a 9.76% decline year-over-year.
- Biomea Fusion, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 3.03M shares, a 40254.68% increase year-over-year.
- Biomea Fusion, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-06-30 was 397.88K shares, a 8.45% increase year-over-year.
- Biomea Fusion, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-03-31 was 375.00K shares, a 79.60% decline year-over-year.
- Biomea Fusion, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 3.85M shares, a 69.50% increase from fiscal 2024.
- Biomea Fusion, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 2.27M shares, a 6.86% decline from fiscal 2023.
- Biomea Fusion, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 2.44M shares, a 52.34% increase from fiscal 2022.
- Biomea Fusion, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 1.60M shares, a 64.04% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 5.16M shares 10-Q · filed 2026-08-05 | |||
| 2025-12-31 | 55.50K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | 3.08M shares derived: sum of 2 quarters · filed 2026-03-24 | 3.48M shares derived: sum of 3 quarters · filed 2026-03-24 | 3.85M shares 10-K · filed 2026-03-24 |
| 2025-09-30 | 3.03M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | 3.42M shares derived: sum of 2 quarters · filed 2025-11-04 | 3.80M shares 10-Q · filed 2025-11-04 | 3.86M shares derived: sum of 4 quarters · filed 2025-11-04 |
| 2025-06-30 | 397.88K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | 772.88K shares 10-Q · filed 2025-08-05 | 834.38K shares derived: sum of 3 quarters · filed 2025-08-05 | 841.88K shares derived: sum of 4 quarters · filed 2025-08-05 |
| 2025-03-31 | 375.00K shares 10-Q · filed 2025-05-05 | 436.50K shares derived: sum of 2 quarters · filed 2025-05-05 | 444.00K shares derived: sum of 3 quarters · filed 2025-05-05 | 810.88K shares derived: sum of 4 quarters · filed 2025-05-05 |
| 2024-12-31 | 61.50K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | 69.00K shares derived: sum of 2 quarters · filed 2025-03-31 | 435.88K shares derived: sum of 3 quarters · filed 2025-03-31 | 2.27M shares 10-K · filed 2025-03-31 |
| 2024-09-30 | 7.50K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-29 | 374.38K shares derived: sum of 2 quarters · filed 2024-10-29 | 2.21M shares 10-Q · filed 2024-10-29 | 2.35M shares derived: sum of 4 quarters · filed 2024-10-29 |
| 2024-06-30 | 366.88K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-31 | 2.21M shares 10-Q · filed 2024-07-31 | 2.34M shares derived: sum of 3 quarters · filed 2024-07-31 | 2.73M shares derived: sum of 4 quarters · filed 2024-07-31 |
| 2024-03-31 | 1.84M shares 10-Q · filed 2024-05-02 | 1.98M shares derived: sum of 2 quarters · filed 2024-05-02 | 2.36M shares derived: sum of 3 quarters · filed 2024-05-02 | 2.48M shares derived: sum of 4 quarters · filed 2024-05-02 |
| 2023-12-31 | 137.50K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | 524.90K shares derived: sum of 2 quarters · filed 2024-03-28 | 639.85K shares derived: sum of 3 quarters · filed 2024-03-28 | 2.44M shares 10-K · filed 2024-03-28 |
| 2023-09-30 | 387.40K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-30 | 502.35K shares derived: sum of 2 quarters · filed 2023-10-30 | 2.30M shares 10-Q · filed 2023-10-30 | 2.53M shares derived: sum of 4 quarters · filed 2023-10-30 |
| 2023-06-30 | 114.94K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-31 | 1.92M shares 10-Q · filed 2023-07-31 | 2.14M shares derived: sum of 3 quarters · filed 2023-07-31 | 2.32M shares derived: sum of 4 quarters · filed 2023-07-31 |
| 2023-03-31 | 1.80M shares 10-Q · filed 2023-05-02 | 2.03M shares derived: sum of 2 quarters · filed 2023-05-02 | 2.21M shares derived: sum of 3 quarters · filed 2023-05-02 | 2.94M shares derived: sum of 4 quarters · filed 2023-05-02 |
| 2022-12-31 | 223.53K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | 406.73K shares derived: sum of 2 quarters · filed 2023-03-28 | 1.14M shares derived: sum of 3 quarters · filed 2023-03-28 | 1.60M shares 10-K · filed 2023-03-28 |
| 2022-09-30 | 183.20K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | 913.92K shares derived: sum of 2 quarters · filed 2022-11-07 | 1.38M shares 10-Q · filed 2022-11-07 | 2.72M shares derived: sum of 4 quarters · filed 2022-11-07 |
| 2022-06-30 | 730.72K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-01 | 1.20M shares 10-Q · filed 2022-08-01 | 2.54M shares derived: sum of 3 quarters · filed 2022-08-01 | 2.94M shares derived: sum of 4 quarters · filed 2022-08-01 |
| 2022-03-31 | 465.46K shares 10-Q · filed 2022-05-16 | 1.81M shares derived: sum of 2 quarters · filed 2022-05-16 | 2.21M shares derived: sum of 3 quarters · filed 2022-05-16 | 2.85M shares derived: sum of 4 quarters · filed 2022-05-16 |
| 2021-12-31 | 1.34M shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | 1.74M shares derived: sum of 2 quarters · filed 2022-02-28 | 2.39M shares derived: sum of 3 quarters · filed 2022-02-28 | 4.46M shares 10-K · filed 2022-02-28 |
| 2021-09-30 | 398.25K shares derived: 10-K 12 month − 3 quarters · filed 2022-02-28 | 1.04M shares derived: sum of 2 quarters · filed 2022-02-28 | 3.11M shares 10-Q · filed 2021-11-03 | |
| 2021-06-30 | 646.74K shares 10-Q · filed 2021-08-11 | 2.71M shares derived: sum of 2 quarters · filed 2021-08-11 | ||
| 2021-03-31 | 2.07M shares 10-Q · filed 2021-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B |